Hogan Lovells

Delia A. Deschaine

Senior Associate
Washington, D.C.

Phone

+1 202 637 5547

Fax

+1 202 637 5910

Email

delia.deschaine@hoganlovells.com

Biography

Delia Deschaine has long represented pharmaceuticals and biotechnology clients in cases involving U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) enforcement and litigation.

She conducts internal investigations, represents clients in civil and criminal investigations, and routinely counsels clients on their compliance obligations under current Good Manufacturing Practices (cGMPs). Delia also works with clients regarding domestic and foreign inspections, including responding to Form FDA 483s and warning letters. Clients turn to Delia for guidance on FDA and DEA regulation of pharmaceuticals, including controlled substances and listed chemicals.

Delia is well-versed in the federal and state regulation of controlled substances. She served as a lawyer in the U.S. Attorney General's Honors Program, Drug Enforcement Administration, and has represented clients in many criminal, civil, and administrative investigations, and litigation brought by and against the DEA. She routinely counsels clients on their compliance obligations under the Controlled Substances Act regarding registration, security, recordkeeping, and reporting, and has represented national organizations in developing their suspicious order monitoring and supply chain integrity programs.

Practices

Administrative and Public Law

Government Relations and Public Affairs

Health Law

Litigation

Pharmaceuticals and Biotechnology Regulatory

Industries

Life Sciences and Health Care

Areas of focus

Judicial Review

Delia's controlled substances experience is informed by her work as a lawyer advocate for a public interest organization, focusing on remedying the legal and systemic barriers that prevent access to addiction treatment services.

Representative experience

Held leading role in high-profile government investigation and subsequent litigation involving wholesale distribution of controlled substances.*

Represented a national pharmacy chain in civil, criminal, and administrative investigations regarding compliance with the CSA and CMEA.

*Matter handled prior to joining Hogan Lovells.

Awards and rankings

- Rising Star, Food & Drugs, *Super Lawyers*, 2018

Latest thinking and events

- Hogan Lovells Publications
  - DEA launches new ARCOS enhancement to help manufacturers and distributors "know your customer" and detect suspicious orders *Pharmaceutical and Biotechnology Alert*
- Webinar
  - CBD and the changing regulatory landscape for hemp-derived products
- Hogan Lovells Publications
  - President signs 2018 Farm Bill with hemp reforms – implications for regulatory oversight of hemp-derived products including cannabidiol (CBD) *Pharmaceutical and Biotechnology Alert*
- Hogan Lovells Publications
  - FDA finalizes two guidances clarifying DSCSA enforcement exemptions and issues product identifier Q&A *Pharmaceutical and Biotechnology alert*

Administrative Procedure Act

Pharmaceuticals and Biotechnology

Medical Devices

Health Care Services

Hospitals and Health Care Providers

Controlled Substances and DEA

Product Development and Approval

Education and admissions

Education

J.D., University of Maryland, Francis King Carey School of Law, cum laude, Health Law Certificate, Health Law Moot Court, 2010

B.A., Manhattan College, Board of Trustees Scholar, 2000

Memberships

Member, New to Food and Drug Law Planning Committee, Food and Drug Law Institute (2018-2019)

Bar admissions and qualifications

District of Columbia

Maryland

- Hogan Lovells Publications
  - Just in time: FDA finalizes guidance on assessment of abuse potential of drugs *Focus On Regulation*
- Blog Post
  - Don't Blink: 9th Circuit Issues Pivotal Decision on Enforcement of CSA Against Cannabis-ness